A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP)

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Kantarjian HM, Gattermann N, O'Brien SG, Bhalla K, Hochhaus A, Cervantes F, Alland L, Ottmann O, Giles F, Le Coutre P

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 42nd Meeting of the American Society of Clinical Oncology

Year of Conference: 2006

Pages: 345S-345S

Publisher: Journal of Clinical Oncology: American Society of Clinical Oncology

Library holdings: Search Newcastle University Library for this item

ISBN:

ePrints